Published in Cancer Res on March 01, 1989
Immune escape mechanisms of intraocular tumors. Prog Retin Eye Res (2009) 1.07
High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. Br J Cancer (1998) 0.95
In silico driven redesign of a clinically relevant antibody for the treatment of GD2 positive tumors. PLoS One (2013) 0.88
HLA expression in a primary uveal melanoma, its cell line, and four of its metastases. Br J Ophthalmol (1997) 0.86
Radioimmunoscintigraphy and immunohistochemistry with melanoma-associated monoclonal antibodies in choroidal melanoma: a comparison of the clinical and immunohistochemical results. Br J Ophthalmol (1990) 0.84
Theranostic impact of NG2/CSPG4 proteoglycan in cancer. Theranostics (2015) 0.82
Immunoscintigraphy with three step monoclonal pretargeting technique in diagnosis of uveal melanoma: preliminary results. Br J Ophthalmol (1994) 0.79
HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncoimmunology (2017) 0.75
erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science (1987) 6.36
Oncogenic response of rat skin, lungs, and bones to vinyl chloride. Cancer Res (1971) 4.39
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 4.23
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Isolation of human T and B lymphocytes by rosette formation with 2-aminoethylisothiquronium bromide (AET) -treated sheep red blood cells with monkey red blood cells. J Immunol Methods (1976) 2.30
Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation (1981) 2.29
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest (1991) 2.08
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer (1991) 1.95
Inhibition of ErbB-2 mitogenic and transforming activity by RALT, a mitogen-induced signal transducer which binds to the ErbB-2 kinase domain. Mol Cell Biol (2000) 1.85
Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82
Structural studies of murine I-E and human DR antigens. Mol Immunol (1979) 1.79
EGF receptor and erbB-2 tyrosine kinase domains confer cell specificity for mitogenic signaling. Science (1990) 1.76
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol (1989) 1.73
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Characterization of the WIDR: a human colon carcinoma cell line. In Vitro (1979) 1.69
Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today (1995) 1.69
Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol (1990) 1.66
Structural polymorphism of human DR antigens. Nature (1979) 1.63
DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization. J Exp Med (1979) 1.63
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
A rapid method for direct HL-A typing of cultured lymphoid cells. J Immunol (1971) 1.55
Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer (1993) 1.55
Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer (1981) 1.55
Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol (2001) 1.54
The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Mol Cell Biol (1990) 1.52
Characterization of Ia antigens in mouse serum. J Immunol (1976) 1.51
Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res (1992) 1.47
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today (1999) 1.47
Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res (1999) 1.46
Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Methods (1983) 1.45
Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens (2005) 1.45
Role of endothelin-1 in neovascularization of ovarian carcinoma. Am J Pathol (2000) 1.44
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res (1990) 1.43
TAP off--tumors on. Immunol Today (1997) 1.43
The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand. New Biol (1990) 1.42
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol (1999) 1.41
Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent. J Immunol (1980) 1.38
Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer (1990) 1.36
The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency. Mol Cell Biol (1991) 1.36
Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens (2003) 1.36
Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res (2000) 1.35
Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer (1996) 1.35
Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer (1992) 1.34
The evolutionarily conserved EBR module of RALT/MIG6 mediates suppression of the EGFR catalytic activity. Oncogene (2007) 1.33
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma (1989) 1.32
Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol (1978) 1.31
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol (1986) 1.30
MHC antigens in human melanomas. Semin Cancer Biol (1991) 1.28
Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res (1984) 1.26
Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today (1999) 1.26
Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res (2001) 1.25
Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res (1983) 1.25
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A (1992) 1.24
Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res (1994) 1.24
Changes in expression of alpha 6/beta 4 integrin heterodimer in primary and metastatic breast cancer. Br J Cancer (1992) 1.24
Constitutive phosphorylation of Shc proteins in human tumors. Oncogene (1995) 1.23
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. J Immunol (1985) 1.23
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med (1999) 1.22
Changes in Ia-like antigen expression on malignant human cells. Immunogenetics (1981) 1.22
Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. J Immunol (1981) 1.21
HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res (1998) 1.21
Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest (1991) 1.21
Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A (1989) 1.20
Evaluation of C3 receptors on lymphoid cells with different complement sources. J Immunol (1974) 1.19
Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer (1996) 1.18
Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. J Immunol (1987) 1.18
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest (1998) 1.17
Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res (1988) 1.17
Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. J Immunol (1989) 1.17
Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer (1991) 1.16
Stimulation of human T lymphocytes by PHA-activated autologous T lymphocytes: analysis of the role of Ia-like antigens with monoclonal antibodies. Immunogenetics (1981) 1.16
CSPG4 in cancer: multiple roles. Curr Mol Med (2010) 1.15
The lymphocytotoxic reaction: the mechanism of rabbit complement action. J Immunol (1971) 1.15
The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics (1983) 1.15
Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res (1995) 1.13
Identification and biochemical characterization of novel putative substrates for the epidermal growth factor receptor kinase. J Biol Chem (1992) 1.13